Linfoma intestinal tipo MALT en una paciente con enfermedad de Crohn: ¿asociación causal o casual?

Article information

Se presenta el caso de una mujer de 79 años diagnosticada hacía 3 años de enfermedad de Crohn del colon, que desarrolló un linfoma tipo MALT de colon derecho estando en tratamiento con mesalazina y no habiendo recibido previamente fármacos inmunodepresores ni infliximab. Se analiza la posible asociación entre la enfermedad de Crohn y el desarrollo de linfomas intestinales: incidencia, mecanismos patogénicos, estrategia diagnóstica, tratamiento y pronóstico de esta neoplasia, haciendo alusión fundamentalmente al linfoma MALT de colon.

We present the case of a 79-year-old woman who had received a diagnosis of Crohn's disease 3 years previously and who developed a mucosa-associated lymphoid tissue (MALT) lymphoma of the right colon while undergoing treatment with mesalazine. The patient had not received immunosuppressive drugs or infliximab. The possible association between Crohn's disease and the development of intestinal lymphomas is analyzed. The incidence, pathogenic mechanisms, diagnostic strategy, treatment and prognosis of these neoplasms are described, mainly with reference to MALT lymphomas of the colon.

Full text is only aviable in PDF

Bibliograf¿a

[1]

Intestinal and extraintestinal cancer in Crohn's disease: follow-up of a populationbased cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004; 19:287-93.

[2]

Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121:1080-7.

[3]

Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91:854-62.

[4]

Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347:215-9.

[5]

Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on inmunosuppresive therapy but overall risk is low. Gut. 2000; 47:514-9.

[6]

Laparoscopy-assisted colon resection for mucosa-associated lymphoid tissue (MALT) lymphoma in the cecum. Hepatogastroenterology. 2003; 50:1003-5.

[7]

Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther. 2002; 16:1225-32.

[8]

Extraintestinal cancers in inflammatory bowel disease. Cancer. 1985; 56:2914-21.

[9]

Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2000; 95:2308-12.

[10]

Primary intestinal lymphoma complicating Crohn's disease. J Clin Gastroenterol. 2003; 36:332-6.

[11]

Lymphoma and Hashimoto's thyroiditis. J Laryngol Otol. 1995; 109:781-3.

[12]

Lymphoid proliferations of the salivary glands. Am J Clin Pathol. 1999; 111:94-103.

[13]

Role of Helicobacter pylori in the pathogenesis of gastric carcinoma and progression of lymphoid nodules to lymphoma. Can J Gastroenterol. 1999; 13:224-7.

[14]

Lymphoma incidence, cyclosporine, and the evolution and mayor impact of malignancy following organ transplantation. Trasplantation Proc. 1997; 29:825-7.

[15]

Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol. 1999; 26:1705-14.

[16]

The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology. 1999; 117:1433-7.

[17]

Indicaciones de tratamiento con infliximab. ¿Hasta cuándo hay que administrarlo? Evaluación del riesgo-beneficio. Gastroenterol Hepatol. 2004; 27:172-6.

[18]

A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood. 1994; 84:1361-91.

[19]

Extranodal malignant lymphoma arising from mucosa-assisted lymphoid tissue. Cancer. 1984; 53:2515-24.

[20]

Linfomas del estómago. El linfoma MALT como modelo de linfoma extranodal. Rev Esp Enf Dig. 2004; 96:8-61.